Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

catumaxomab

A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
2015
2015
AbstractPurposeThe aim of the study was to evaluate the safety and determine the maximum tolerated dose (MTD) of intravenous… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
BackgroundThe peritoneum is one of the most frequent sites of recurrent gastric carcinoma after curative treatment, despite the… Expand
Is this relevant?
2013
2013
Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell adhesion molecule (EpCAM) and the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2010
Review
2010
Catumaxomab is a trifunctional antibody (trAb) characterized by its unique ability to bind three different cell types: tumor… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The Triomab® family of trifunctional, bispecific antibodies that maintain an IgG-like shape are novel tumor targeting agents… Expand
Is this relevant?
2010
2010
AIMS Catumaxomab is the first EMEA approved trifunctional anti-EpCAM×anti-CD3 antibody for the treatment of cancer patients with… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Purpose: Malignant ascites in ovarian carcinoma patients is associated with poor prognosis and reduced quality of life. The… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?